Phaseline

Targets › SGCB

SGCB (Beta-sarcoglycan): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Neurology; next expected readout Aug 2028.

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. (UniProt, Q16585)

Open in Phaseline: the race on SGCB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sarepta TherapeuticsSRP-9003
Gene transfer therapy encoding beta-sarcoglycan (β-SG); scAAVrh74.MHCK7.hSGCB
SGCBPhase 3Limb-girdle Muscular Dystrophy; Limb Girdle Muscular DystrophyAug 2028

Conditions

Limb-girdle Muscular Dystrophy (1) Limb Girdle Muscular Dystrophy (1)

Modalities

other (1)

Companies

Sarepta Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.